"With Apalutamide's Regulatory Approval for Non-Metastatic (M0) CRPC, Why Not Move Agents Even Earlier Into the Castration-Sensitive Biochemically-Recurrent Disease State?"
One year ago, in this column, I highlighted the non-metastatic (M0) castration-resistant prostate cancer (CRPC) disease state as a fruitful area for clinical trial exploration.1 As part of that article, I emphasized the concept of testing low toxicity, high efficacy agents from metastatic CRPC in earlier disease states. Two of the randomized, phase 3 trials have just came out and the results are quite impressive.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.